Enzymes for Research, Diagnostic and Industrial Use
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Catalog | Product Name | EC No. | CAS No. | Source | Price |
---|---|---|---|---|---|
NATE-0051 | α-Lytic Protease M190A Mutant, Recombinant | Inquiry |
Proteases are essential enzymes that facilitate the hydrolysis of peptide bonds, playing critical roles in various biological processes, including protein turnover, signal transduction, and metabolic regulation. Among different classes of proteases, alpha-lytic protease (aLP) has garnered particular interest due to its unique specificity and adaptability, making it an invaluable tool in proteomic applications.
Alpha-lytic protease is derived from the bacterium Bacillus subtilis. It was first characterized in the late 20th century and was found to possess a balanced specificity for certain amino acids, which allowed for predictable cleavage patterns. The wild-type aLP cleaves after the residues T (threonine), A (alanine), S (serine), and V (valine), which has made it particularly useful in experimental and clinical settings for protein analysis, including directed protein cleavage and protein mapping.
In proteomic research, the ability to selectively cleave proteins into manageable peptide fragments is fundamental for mass spectrometry (MS) analysis. The specificity of aLP allows for the generation of peptides that can be analyzed to gain information about protein structure, function, and interactions. The M190A variant, a site-directed mutant, offers an alternative specificity profile, cleaving after the hydrophobic residues M (methionine), F (phenylalanine), and L (leucine). This change can considerably broaden the scope of proteomic investigations by allowing researchers to target different sets of proteins or fragments that may not be amenable to the wild-type enzyme.
The structure of alpha-lytic protease is typical of serine proteases, featuring a catalytic triad composed of serine, histidine, and aspartate residues. This triad plays a crucial role in the enzyme's catalytic mechanism, facilitating the nucleophilic attack on the peptide bond of the substrate.
The M190A mutation replaces methionine at position 190 with alanine. This seemingly minor alteration can lead to significant changes in the enzyme's conformation and, consequently, its specificity. The removal of the bulky side chain of methionine creates a more open environment in the substrate binding site, allowing the enzyme to accommodate larger hydrophobic amino acids such as phenylalanine and leucine. Structural studies, including X-ray crystallography and NMR spectroscopy, have provided valuable insights into how this mutation influences overall folding and functionality.
The primary characteristic that distinguishes M190A from the wild-type aLP is its cleavage specificity. By targeting M, F, and L residues, M190A expands the range of proteins that can be effectively cleaved and analyzed.
ALP M190A is widely used in proteomics research for protein digestion and peptide mapping. By cleaving proteins at specific residues, it generates peptides that can be analyzed by mass spectrometry or other techniques. This allows researchers to identify proteins, determine their post-translational modifications, and study protein-protein interactions.
In drug discovery and development, ALP M190A can be used to identify potential therapeutic targets. By digesting disease-related proteins with the mutant protease, researchers can generate peptides that may contain regions of interest for drug design. This approach can help in the identification of novel drug targets and the development of targeted therapies.
In conclusion, the M190A mutant of alpha-lytic protease is a valuable tool in proteomics with unique properties and applications. Its specific cleavage specificity, structural characteristics, and diverse functions make it an important asset for researchers in the field. Further studies on ALP M190A will likely lead to new insights into proteomics and contribute to the development of novel therapeutic strategies and diagnostic tools.